Jasper Therapeutics (JSPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the stock and has a $15.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the potential of Jasper Therapeutics’ Briquilimab. The data from the CIndU trial is promising, showing a strong dose-response relationship and competitive efficacy and safety compared to competitors. This positions Briquilimab as a potentially attractive commercial opportunity, especially given the lack of competition from existing treatments like Xolair and Dupixent in the CIndU market.
Biliouris also points out the favorable safety profile of Briquilimab, which differentiates it from other treatments by not being associated with severe adverse effects or pigmentation changes. The upcoming data on Briquilimab’s performance in CSU could further bolster its market potential, with expectations of a significant upside. This combination of promising trial results, competitive positioning, and a positive safety profile underpins the Buy rating for Jasper Therapeutics’ stock.